Trial intelligence / Profile preview

Creon versus placebo for pancreatic exocrine insufficiency in adults with type 1 diabetes

2013-002748-10Phase 4Active

Sponsor
Fundación para la Investigación en Enfermedades del Aparato Digestivo
Start
Sep 2013
Modality
Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 4, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) comparing Creon with Placebo (2 arms). Primary endpoint: Change in fat digestion measured by 13C-MTG breath test. Started Sep 2013; status: active.

02

Drugs

pancreatin
03

Conditions

exocrine pancreatic insufficiency (EPI)

Beyond the preview

Go deeper on 2013-002748-10.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-002748-10.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call